|
KaryOpharm Therapeutics Inc. (KPTI) Avaliação DCF |
Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
Design Profissional: Modelos Confiáveis E Padrão Da Indústria
Pré-Construídos Para Uso Rápido E Eficiente
Compatível com MAC/PC, totalmente desbloqueado
Não É Necessária Experiência; Fácil De Seguir
Karyopharm Therapeutics Inc. (KPTI) Bundle
Otimize sua eficiência e melhore a precisão com a nossa calculadora DCF (KPTI)! Utilizando dados reais da KaryOpharm Therapeutics Inc. e suposições personalizáveis, essa ferramenta o capacita a prever, analisar e valorizar (KPTI), assim como um investidor experiente.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 108.1 | 209.8 | 157.1 | 146.0 | 145.2 | 167.5 | 193.3 | 222.9 | 257.2 | 296.6 |
| Revenue Growth, % | 0 | 94.12 | -25.14 | -7.03 | -0.54508 | 15.35 | 15.35 | 15.35 | 15.35 | 15.35 |
| EBITDA | -167.9 | -97.0 | -139.3 | -118.4 | -38.6 | -114.8 | -132.4 | -152.7 | -176.2 | -203.2 |
| EBITDA, % | -155.3 | -46.22 | -88.69 | -81.09 | -26.58 | -68.52 | -68.52 | -68.52 | -68.52 | -68.52 |
| Depreciation | 1.0 | .8 | .6 | .5 | .3 | .8 | .9 | 1.0 | 1.2 | 1.3 |
| Depreciation, % | 0.89929 | 0.37604 | 0.39536 | 0.36293 | 0.2341 | 0.45354 | 0.45354 | 0.45354 | 0.45354 | 0.45354 |
| EBIT | -168.8 | -97.8 | -139.9 | -119.0 | -38.9 | -115.2 | -132.9 | -153.4 | -176.9 | -204.1 |
| EBIT, % | -156.2 | -46.6 | -89.08 | -81.46 | -26.81 | -68.79 | -68.79 | -68.79 | -68.79 | -68.79 |
| Total Cash | 273.5 | 228.6 | 278.0 | 191.4 | 108.7 | 159.1 | 183.5 | 211.7 | 244.2 | 281.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 12.9 | 22.5 | 47.1 | 27.0 | 30.8 | 30.9 | 35.7 | 41.1 | 47.5 | 54.7 |
| Account Receivables, % | 11.92 | 10.72 | 29.98 | 18.46 | 21.18 | 18.45 | 18.45 | 18.45 | 18.45 | 18.45 |
| Inventories | 2.6 | 4.1 | 4.2 | 3.0 | 4.7 | 4.2 | 4.8 | 5.5 | 6.4 | 7.4 |
| Inventories, % | 2.45 | 1.96 | 2.69 | 2.08 | 3.26 | 2.49 | 2.49 | 2.49 | 2.49 | 2.49 |
| Accounts Payable | 4.5 | 1.6 | 2.8 | 3.1 | 5.1 | 4.1 | 4.8 | 5.5 | 6.3 | 7.3 |
| Accounts Payable, % | 4.12 | 0.76399 | 1.77 | 2.14 | 3.52 | 2.46 | 2.46 | 2.46 | 2.46 | 2.46 |
| Capital Expenditure | -.1 | -5.7 | -.1 | .0 | -.1 | -1.0 | -1.2 | -1.4 | -1.6 | -1.8 |
| Capital Expenditure, % | -0.13415 | -2.72 | -0.07512383 | 0 | -0.09777123 | -0.60588 | -0.60588 | -0.60588 | -0.60588 | -0.60588 |
| Tax Rate, % | -0.07464152 | -0.07464152 | -0.07464152 | -0.07464152 | -0.07464152 | -0.07464152 | -0.07464152 | -0.07464152 | -0.07464152 | -0.07464152 |
| EBITAT | -169.1 | -98.0 | -140.2 | -119.2 | -39.0 | -115.2 | -132.9 | -153.4 | -176.9 | -204.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -179.3 | -116.8 | -163.3 | -97.0 | -42.3 | -116.1 | -138.0 | -159.2 | -183.6 | -211.8 |
| WACC, % | 11.65 | 11.65 | 11.65 | 11.65 | 11.65 | 11.65 | 11.65 | 11.65 | 11.65 | 11.65 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -569.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -216 | |||||||||
| Terminal Value | -2,238 | |||||||||
| Present Terminal Value | -1,290 | |||||||||
| Enterprise Value | -1,859 | |||||||||
| Net Debt | 37 | |||||||||
| Equity Value | -1,896 | |||||||||
| Diluted Shares Outstanding, MM | 127 | |||||||||
| Equity Value Per Share | -14.95 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to develop various scenarios.
- Real-World Data: Karyopharm Therapeutics Inc.'s (KPTI) financial data pre-filled to accelerate your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value for you.
- Customizable and Professional: A sleek Excel model that adjusts to your valuation requirements.
- Built for Analysts and Investors: Perfect for testing projections, validating strategies, and enhancing efficiency.
Key Features
- Customizable Financial Inputs: Adjust essential metrics such as revenue growth, EBITDA %, and capital investments.
- Instant DCF Valuation: Quickly computes intrinsic value, NPV, and additional financial metrics.
- High-Precision Accuracy: Leverages Karyopharm’s actual financial data for credible valuation results.
- Streamlined Scenario Analysis: Effortlessly evaluate various assumptions and analyze different outcomes.
- Efficiency Booster: Remove the complexity of creating intricate valuation models from the ground up.
How It Works
- 1. Access the Template: Download and open the Excel file featuring Karyopharm Therapeutics Inc. (KPTI) preloaded data.
- 2. Modify Assumptions: Adjust key parameters such as growth rates, WACC, and capital expenditures.
- 3. See Results Instantly: The DCF model automatically computes intrinsic value and NPV.
- 4. Explore Scenarios: Evaluate multiple forecasts to assess various valuation outcomes.
- 5. Present with Assurance: Deliver professional valuation insights to back your strategic decisions.
Why Choose Karyopharm Therapeutics Inc. (KPTI)?
- Innovative Treatments: Pioneering therapies targeting cancer and other serious diseases.
- Robust Pipeline: A diverse portfolio of drug candidates in various stages of development.
- Expert Leadership: A team of seasoned professionals with extensive industry experience.
- Commitment to Research: Ongoing investment in research and development to advance healthcare solutions.
- Strong Partnerships: Collaborations with leading organizations enhance our capabilities and reach.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and trustworthy valuation models for analyzing Karyopharm Therapeutics Inc. (KPTI) in their portfolios.
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions regarding Karyopharm Therapeutics Inc. (KPTI).
- Consultants and Advisors: Offer clients precise valuation insights related to Karyopharm Therapeutics Inc. (KPTI) stock.
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling with Karyopharm Therapeutics Inc. (KPTI).
- Biotech Enthusiasts: Gain insights into how biotech firms like Karyopharm Therapeutics Inc. (KPTI) are valued in the financial markets.
What the Template Contains
- Preloaded KPTI Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.